FDA grants orphan drug status to Ractigen’s RAG-18 for DMD and BMD
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) product candidate for the treatment of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).